Latest News Archive

Please select Category, Year, and then Month to display items

UFS wins top awards at the 2024 Mace Excellence Awards

05 December 2024 | Story Dr Cindé Greyling | Photo Kaleidoscope

MACE Winners 2024 — From left to right: Burneline Kaars (Head: Employee Wellness and Organisational Development), Dr WP Wahl (Student Life Director), Linda Greyling (Senior Officer: Special Projects, Student Recruitment Services), Gerben Van Niekerk (Senior Officer: Kovsie Support Services), Malia Maranyane (Senior Officer: Undergraduate Marketing, Student Recruitment Services), Nomonde Mbadi (Student Recruitment Services Director), and Susan Van Jaarsveld (Senior Director: Human Resources).

On 28 November 2024, the University of the Free State (UFS) did it again – reigned as champions at the annual Marketing, Advancement and Communication in Education (MACE) Excellence Awards and walking away with two of the top awards: the MACE Award for Outstanding Research and the Severus Cerff Award for Consistent Excellence.

KovsieX was named the overall winner of the MACE Award for Outstanding Research. This award is made to the entry with the highest score in research, clearly demonstrating how research has supported the strategic objectives of the institution and the project. KovsieX is a multiplatform approach designed to leverage the strengths of diverse media channels. This digitalisation aligns with Vision 130, leveraging emerging technologies to enhance teaching and learning quality and efficiency of non-academic support structures and systems.

The UFS’ entries were of such high quality that the university won the sought-after Severus Cerff Award for Consistent Excellence. This award is based on the number of entries entered by an institution and the number and level of those entries winning awards. The award is therefore made to the institution with the highest success ratio.

Furthermore, the UFS Matriculant of the Year event received a Silver Award – entries scoring 5.75 or higher earn a Silver Award, placing this event among some of the top achievers in the events category. Three UFS entries received Gold Awards and were the winners in their respective categories: KovsieChat (Digital Channels), 2024 Women’s Day Breakfast (Events), and KovsieX (Stakeholder Engagement Campaigns). This is a magnificent achievement for the UFS.

"Winning a MACE award at this early stage is proof that KovsieX is not just meeting national standards – it’s setting them. If we can achieve this level of excellence now, imagine how we’ll compete on the global stage when the project is fully realised,” says Gerben van Niekerk, Student Media Manager.

Lacea Loader, Senior Director: Communication and Marketing and Coordinator of the MACE Excellence Awards, explained that a record number of entries were received for the Excellence Awards this year. “We are ecstatic about the direction of communication at the UFS and that the university has been able to maintain the quality of its entries in recent years,” says Loader.

The MACE Excellence Awards takes place annually as part of the MACE National Conference, recognising and celebrating excellence and the achievements of specialists and practitioners in marketing, advancement, and communication in the higher-education sector. This year, the Cape Peninsula University of Technology (CPUT) hosted the conference from 27 to 28 November 2024.

In 2023, the UFS won 11 awards, including the Chairperson’s Award of Excellence.

News Archive

Nuclear Medicine on the forefront of cancer research

2017-07-10

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma. The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept